DGAP-News: APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

APEIRON Biologics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform for the advancement of APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors.